Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 14/20 | 0.55 |
| ▸ | PPARG | P37231 | 13/20 | 0.55 |
| ▸ | PPARD | Q03181 | 5/20 | 0.55 |
| ▸ | SRR | Q9GZT4 | 4/20 | 0.54 |
| ▸ | PSAT1 | Q9Y617 | 2/20 | 0.53 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL720353 | 1.00 | PPARA (0.55) | PPARAPPARGPPARDSRRPSAT1 | |
| SCHEMBL1368490 | 1.00 | PPARA (0.55) | PPARAPPARGPPARDSRRPSAT1 | |
| SCHEMBL12581017 | 0.86 | SRR (0.42) | PPARAPPARGPPARDSRRPSAT1 | |
| SCHEMBL14392119 | 0.85 | PPARG (0.81) | PPARAPPARGPPARDSRRPSAT1 | |
| Methylamine SCHEMBL5607639 | 0.84 | SLC7A5 (0.56) | PPARAPPARGPPARDSRRPSAT1 | |
| SCHEMBL16451001 | 0.84 | ESR1 (0.45) | PPARAPPARGPPARDSRRPSAT1 | |
| SCHEMBL3466702 | 0.84 | PPARA (0.56) | PPARAPPARGPPARDSRRPSAT1 | |
| SCHEMBL4451311 | 0.84 | PPARA (0.56) | PPARAPPARGPPARDSRRPSAT1 | |
| SCHEMBL4941128 | 0.84 | PPARA (0.56) | PPARAPPARGPPARDSRRPSAT1 | |
| SCHEMBL9628212 | 0.83 | SRR (0.70) | PPARAPPARGPPARDSRRPSAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12291494-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2025-05-06 | — | — | US | claimed |
| US-20240279157-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2024-08-22 | — | — | US | claimed |
| US-11753365-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2023-09-12 | — | — | US | claimed |
| CN-116602950-A | Methods of treating fibrosis | 诺格拉制药有限公司 | 2023-08-18 | — | — | CN | claimed |
| US-20220194894-A1 | PROCESS OF MAKING 3-(4'-AMINOPHENYL)-2-METHOXYPROPIONIC ACID, AND ANALOGS AND INTERMEDIATES THEREOF | NOGRA PHARMA LIMITED (IE) | 2022-06-23 | — | — | US | claimed |
| US-20220033346-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2022-02-03 | — | — | US | claimed |
| CN-113825739-A | Process for preparing 3- (4' -aminophenyl) -2-methoxypropionic acid and analogs and intermediates thereof | 诺格拉制药有限公司 | 2021-12-21 | — | — | CN | claimed |
| EP-3921299-A1 | PROCESS OF MAKING 3-(4'-AMINOPHENYL)-2-METHOXYPROPIONIC ACID, AND ANALOGS AND INTERMEDIATES THEREOF | Nogra Pharma Limited (IE) | 2021-12-15 | — | — | EP | claimed |
| EP-3914227-A1 | COMPOSITIONS FOR USE IN PREVENTING ACNE | Nogra Pharma Limited (IE) | 2021-12-01 | — | — | EP | claimed |
| US-11046641-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2021-06-29 | — | — | US | claimed |
| EP-2355810-A2 | METHODS FOR PREVENTING OR REDUCING CARCINOGENESIS OR OXIDATIVE STRESS | Giuliani International Limited (IE) | 2011-08-17 | — | — | EP | claimed |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | NOGRA PHARMA LIMITED (IE) | 2011-06-23 | — | — | US | claimed |
| CN-101969943-A | Compounds for the selective treatment of the intestinal immunoinflammatory component of celiac disease | GIULIANI INT LTD | 2011-02-09 | — | — | CN | claimed |
| US-20100305077-A1 | COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE | NOGRA PHARMA LIMITED (IE) | 2010-12-02 | — | — | US | claimed |
| WO-2010063470-A2 | METHODS FOR PREVENTING OR REDUCING CARCINOGENESIS OR OXIDATIVE STRESS | GIULIANI INTERNATIONAL LIMITED (IE) | 2010-06-10 | — | — | WO | claimed |
| EP-2131829-A1 | PPAR-GAMMA AGONISTS FOR THE INDUCTION OF CATIONIC ANTIMICROBIAL PEPTIDE EXPRESSION AS IMMUNOPROTECTIVE STIMULANTS | Giuliani International Limited (IE) | 2009-12-16 | — | — | EP | claimed |
| US-20090048343-A1 | Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field | NOGRA PHARMA LIMITED (IE) | 2009-02-19 | — | — | US | claimed |
| WO-2008104557-A1 | PPAR-GAMMA AGONISTS FOR THE INDUCTION OF CATIONIC ANTIMICROBIAL PEPTIDE EXPRESSION AS IMMUNOPROTECTIVE STIMULANTS | GIULIANI INTERNATIONAL LIMITED (IE) | 2008-09-04 | — | — | WO | claimed |
| EP-1910270-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | Giuliani International Limited (IE) | 2008-04-16 | — | — | EP | claimed |
| WO-2007010516-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | GIULIANI INTERNATIONAL LIMITED (IE) | 2007-01-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194894-A1 | PROCESS OF MAKING 3-(4'-AMINOPHENYL)-2-METHOXYPROPIONIC ACID, AND ANALOGS AND INTERMEDIATES THEREOF | PPARA, PPARG, PPARD | PPARA 1/4885PPARG 2/4885PPARD 3/4885 |
| US-20100305077-A1 | COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE | SI, FABP2, NFKBIA | PPARA 1519/4885PPARG 838/4885PPARD 938/4885 |
| US-11753365-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | PPARA 648/4885PPARG 669/4885PPARD 1293/4885 |
| US-20240279157-A1 | METHODS OF TREATING FIBROSIS | MMP1, MMP8, FABP2 | PPARA 648/4885PPARG 669/4885PPARD 1293/4885 |
| US-20090048343-A1 | Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field | EGFR, ERBB3, FGFR3 | PPARA 9/4885PPARG 4/4885PPARD 12/4885 |
| US-12291494-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | PPARA 648/4885PPARG 669/4885PPARD 1293/4885 |
| US-11046641-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | PPARA 648/4885PPARG 669/4885PPARD 1293/4885 |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | PPARG, FABP2, PPARD | PPARA 4/4885PPARG 1/4885PPARD 3/4885 |
| US-20220033346-A1 | METHODS OF TREATING FIBROSIS | MMP1, MMP8, FABP2 | PPARA 648/4885PPARG 669/4885PPARD 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.